Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Stopped Due to a Dose Limiting Toxicity in another sister trial with same technology.

Conditions

• HER-2 Gene Amplification
• HER2-positive Gastric Cancer
• HER2-positive Breast Cancer
• HER-2 Protein Overexpression
• Solid Tumor, Adult

Interventions

• BIOLOGICAL: chimeric antigen receptor (CAR) T cell therapy

Sponsor

Bellicum Pharmaceuticals